Venture Kick invests in PANDA Therapeutics

Funding Provisional 90% confidence first seen 31 August 2026, 10:49

PANDA Therapeutics secured €160,000 from Venture Kick to advance its multi-target Alzheimer’s antibody therapy toward clinical development. The coverage says the funds (reported as CHF 150,000) will be used for company formation and business development, including building advisory and CMC/manufacturing readiness plans, as well as IP and regulatory planning for later financing and partnership opportunities. This matters as it supports early-stage progress toward clinical testing for a treatment aiming to target multiple harmful protein deposits (e.g., amyloid-beta and tau) more broadly than current approaches.